u/customs_seizure_sid

all three of mine were in the same bracket, which i had assumed was a safe one. apparently it is a referral one.

open-label extensions are not the same evidence as the randomised phase

this is the clearest explanation of the pattern i have read and it fits all three letters.

Correction to my own post above — I said 15mg and I have been on 5mg since the spring. Same argument, wrong number.

Yes — the comparison threads are apples to oranges and they generate more heat than anything else here.

switching from sema is not a dose conversion, there is no clean equivalence

Saving this one. It is the clearest statement of the stall problem I have read here.

dual GLP-1 and glucagon agonist, and the glucagon arm is the story

Had the conversation with a clinician before stopping rather than after. Considerably easier that way round.

On comparing yourself with the trial number.

SURMOUNT-1 reported roughly 21% mean body weight change at 72 weeks on the highest arm. Three things get dropped every time that figure is quoted here. It is a mean, and the distribution around it is very wide. It is 72 weeks, which is a year and a half. And it is a trial population with trial support, which is not the same as a person with a spreadsheet.

Use it as a rough shape, not a benchmark. A 12% year is inside the ordinary range and people quit over it every week on this board.

Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight.

Address redacted from the screenshot above. Post the wording of the notice, never the header.

Cosigning the domain check. Character by character, every time, and paste it rather than typing it.

Repeat testing before acting is standard practice for a reason: regression to the mean does a lot of work on single outlying values.

Absolute or relative risk reduction?

Went looking for the registered protocol to see whether the endpoint had changed. It had not, which was reassuring and worth checking.

Correcting myself upthread: I gave the completer figure and labelled it intention-to-treat.

Right, and the habits from the losing phase are the part that has to outlive the dose.

Disagree with the framing. Regain is the documented outcome after discontinuation; calling it a personal failure is both wrong and corrosive.

Held 7.5 for five months. Everyone kept asking when I was going to 10. The answer was never, because 7.5 was working.

stalling at 0.25mg is information, not a verdict

How to make a panel worth comparing, which is most of the value people leave on the table.

Standardise the conditions: same lab, same fasting state, same rough time of day, same point in the week, similar hydration. Take a baseline before you change anything. Repeat any surprising value before acting on it. Change one thing at a time if you want to attribute anything to it.

Do that and a year of panels is a trend. Skip it and a year of panels is a collection of unrelated mornings, which is what most of the alarmed posts here are actually describing.

Agreed on comparators. "Superior" means nothing until you know superior to what and at what dose.

one measurement is a point, two is a line, three is a trend

the scale is the least sensitive instrument you own

the glucagon component is why the metabolic story reads differently

if it matters, ask somebody qualified in your own jurisdiction

Agreed on asking what documentation accompanies a shipment. Suppliers who ship regionally usually have a clear answer.

Careful with the rankings. A phase 2 result and a phase 3 result are not on the same evidential footing and cannot be listed in one table.

What do you think the glucagon component is adding, specifically?

A confidence interval is the range of effects compatible with the data. Two trials with overlapping intervals have not disagreed, whatever their point estimates look like next to each other.

comparing reta phase 2 to sema phase 3 is comparing different things

discontinuation rate is a result, not a footnote

Left up. It names both countries and quotes the notice, which is exactly what makes these threads useful.

Not convinced by the attribution. Weight loss alone moves that marker and you have no way to separate the two.

How to make a panel worth comparing, which is most of the value people leave on the table.

Standardise the conditions: same lab, same fasting state, same rough time of day, same point in the week, similar hydration. Take a baseline before you change anything. Repeat any surprising value before acting on it. Change one thing at a time if you want to attribute anything to it.

Do that and a year of panels is a trend. Skip it and a year of panels is a collection of unrelated mornings, which is what most of the alarmed posts here are actually describing.

Came off sema and onto tirz with a two-week gap. The first month was flat and I assumed I had made a mistake. Month two it moved.

the trend line matters more than any single value

one measurement is a point, two is a line, three is a trend

Cardiovascular outcome trials are powered for events, not for weight, and are typically run in a different population with different inclusion criteria. Reading a weight number out of one is reading a secondary endpoint.

The rules where I live changed between two orders six months apart. Nothing was announced; I found out by reading.